PCVXVaxcyte, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 19978
Ticker: PCVX
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2020-06-12
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: PCVX

Detail

Enriched 2026-08-14 20:47

Market cap: $8,876,234,832.7
Shares outstanding (class): 144,397,682
Shares outstanding (weighted): 148,805,278
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 507
Location: SAN CARLOS, CA
Homepage: https://www.vaxcyte.com
Description: Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Market cap and share counts drift.

Funds holding this security

225 funds · 231 positions · $2.69B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$266.49M	0.01%	4,585,888 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$192.84M	0.12%	3,318,448 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$176.39M	0.25%	3,035,437 NS	FIGI
T. Rowe Price Capital Appreciation Fund T. ROWE PRICE CAPITAL APPRECIATION FUND, IN…	—	$147.60M	0.22%	2,539,929 NS	FIGI
Janus Henderson Enterprise Fund JANUS INVESTMENT FUND	—	$131.90M	0.65%	2,269,870 NS	FIGI
Janus Henderson Forty Fund JANUS INVESTMENT FUND	—	$130.23M	0.63%	2,241,120 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$108.01M	0.28%	1,858,643 NS	FIGI
T. Rowe Price Mid-Cap Growth Fund, Inc. T. ROWE PRICE MID-CAP GROWTH FUND, INC.	—	$86.65M	0.38%	1,491,100 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$85.58M	1.15%	1,472,715 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$83.20M	0.10%	1,431,800 NS	FIGI
T. Rowe Price Small-Cap Value Fund, Inc. T. ROWE PRICE SMALL-CAP VALUE FUND, INC.	—	$79.59M	0.86%	1,369,591 NS	FIGI
iShares Russell 2000 Value ETF iShares Trust	IWN	$62.01M	0.50%	1,067,186 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$60.77M	0.75%	1,045,695 NS	FIGI
Janus Henderson Global Life Sciences Fund JANUS INVESTMENT FUND	—	$56.47M	1.09%	971,737 NS	FIGI
Janus Henderson Research Fund JANUS INVESTMENT FUND	—	$50.76M	0.20%	873,455 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERPCVX
FIGI_COMPOSITEBBG009PHHPL8
FIGI_SHARE_CLASSBBG009PHHPP4
CIK0001649094
ISINUS92243G1085
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Vaxcyte is a biopharmaceutical company developing vaccines, fitting the biotechnology industry under healthcare.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.